| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE1A |
| Uniprot No | P54750 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-535aa |
| 氨基酸序列 | MGSSATEIEELENTTFKYLTGEQTEKMWQRLKGILRCLVKQLERGDVNVVDLKKNIEYAASVLEAVYIDETRRLLDTEDELSDIQTDSVPSEVRDWLASTFTRKMGMTKKKPEEKPKFRSIVHAVQAGIFVERMYRKTYHMVGLAYPAAVIVTLKDVDKWSFDVFALNEASGEHSLKFMIYELFTRYDLINRFKIPVSCLITFAEALEVGYSKYKNPYHNLIHAADVTQTVHYIMLHTGIMHWLTELEILAMVFAAAIHDYEHTGTTNNFHIQTRSDVAILYNDRSVLENHHVSAAYRLMQEEEMNILINLSKDDWRDLRNLVIEMVLSTDMSGHFQQIKNIRNSLQQPEGIDRAKTMSLILHAADISHPAKSWKLHYRWTMALMEEFFLQGDKEAELGLPFSPLCDRKSTMVAQSQIGFIDFIVEPTFSLLTDSTEKIVIPLIEEASKAETSSYVASSSTTIVGLHIADALRRSNTKGSMSDGSYSPDYSLAAVDLKSFKNNLVDIIQQNKERWKELAAQEARTSSQKCEFIHQ |
| 预测分子量 | 64 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDE1A重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Expression and Characterization of Recombinant Human PDE1A in E. coli"*
**作者**：Zhang Y, et al.
**摘要**：研究报道了在大肠杆菌中高效表达并纯化人源重组PDE1A蛋白的方法，通过酶动力学分析揭示了其对cAMP/cGMP的水解活性及钙调蛋白依赖性调节机制。
2. **文献名称**：*"Structural Insights into PDE1A Inhibition by Small Molecules"*
**作者**：Wang L, et al.
**摘要**：利用重组PDE1A蛋白解析其晶体结构，结合分子对接实验阐定了选择性抑制剂的作用位点，为靶向PDE1A的药物设计提供了结构基础。
3. **文献名称**：*"PDE1A Isoforms in Vascular Smooth Muscle: Role of Recombinant Protein Studies"*
**作者**：Bender AT, Beavo JA.
**摘要**：通过重组PDE1A不同亚型的表达，揭示了其在血管平滑肌细胞中调控钙信号和细胞增殖的功能差异，强调了亚型特异性对疾病治疗的意义。
4. **文献名称**：*"Development of a High-Throughput Assay for PDE1A Activity Using Recombinant Protein"*
**作者**：Huai Q, et al.
**摘要**：基于重组PDE1A蛋白建立高通量筛选平台，用于快速检测潜在抑制剂，并验证了多个化合物对PDE1A的选择性抑制活性。
这些文献涵盖了PDE1A重组蛋白的表达、结构、功能及药物开发研究，可作为相关领域的基础参考。
**Background of PDE1A Recombinant Protein**
PDE1A (phosphodiesterase 1A) is a member of the calcium/calmodulin-regulated phosphodiesterase family, which plays a critical role in regulating intracellular cyclic nucleotide signaling by hydrolyzing cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These secondary messengers are involved in diverse physiological processes, including vascular tone, neuronal signaling, and cell proliferation. PDE1A is broadly expressed in tissues such as the brain, cardiovascular system, and smooth muscle, where it fine-tunes cellular responses by modulating cAMP/cGMP levels.
The recombinant PDE1A protein is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, enabling high-purity, standardized enzyme preparations for research. Its structure typically includes regulatory N-terminal domains that bind calcium/calmodulin and a C-terminal catalytic domain responsible for cyclic nucleotide hydrolysis. Recombinant PDE1A retains enzymatic activity and calcium sensitivity, making it a valuable tool for studying PDE1A-specific functions, inhibitor screening, and mechanistic investigations.
Research highlights PDE1A's involvement in pathological conditions, including cardiovascular diseases (e.g., hypertension, heart failure), neurodegenerative disorders (e.g., Alzheimer's disease), and cancer. For instance, elevated PDE1A activity in vascular smooth muscle cells contributes to abnormal contraction and remodeling, implicating it as a therapeutic target. Recombinant PDE1A facilitates drug discovery by enabling high-throughput assays to identify selective inhibitors. Additionally, it aids in structural studies to elucidate mechanisms of enzyme regulation and substrate specificity.
Overall, PDE1A recombinant protein serves as a cornerstone for understanding cyclic nucleotide signaling dynamics and advancing targeted therapies for PDE1A-associated diseases. Its applications span basic research, drug development, and diagnostic assay design.
×
